The Pre-clinical investigation laboratory is developing the next generation of PDX models, from drug-resistant tumors, metastatic cancer to humanized models.
LIP services includes:
• Preclinical pharmacology & pharmacodynamics of anti-cancer drugs
• Identification of predictive biomarkers of response and resistance to anti-cancer agents
• Collaboration with many national and European academics & pharmaceutical companies
We have established a collection of PDX from primary and metastatic breast tumours, coupled with molecular annotation including cancer panel targeted sequencing as well as transcriptomic and proteomic profiles.
The Pre-clinical investigation laboratory is a member of the EurOPDX Consortium. EurOPDX is supported by the European Union's Horizon 2020 research and innovation programme under the grant agreement No. 731105 EDIReX